Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

EF Hutton Maintains Buy on AFC Gamma, Lowers Price Target to $21

EF Hutton analyst Gaurav Mehta maintains AFC Gamma (NASDAQ:AFCG) with a Buy and lowers the price target from $22 to $21.

byBenzinga Newsdesk

March 8, 2023

1 minute read

EF Hutton analyst Gaurav Mehta maintains AFC Gamma (NASDAQ:AFCG) with a Buy and lowers the price target from $22 to $21.

Dogecoin Leaps On Elon Musk’s Reported Twitter Payments Plan: Why DOGE Supporters Are Excited

By Bibhu Pattnaik

Today, 5:56 AM

Dogecoin (CRYPTO: DOGE) surged more than 10% to an intraday high of $0.095655 on Tuesday, extending this week's gain after a report that Twitter CEO

$DOGE

News

Kiromic BioPharma Provides Update on IND Filings on its Off-the-Shelf, Allogeneic CAR-T for Solid Tumors

By Michael Horton

Today, 5:56 AM

Kiromic BioPharma, Inc. (NASDAQ:KRBP) Two INDs were submitted to the FDA in May 2021 for the first-in-human off-the-shelf allogeneic CAR-T for Solid Tumors. FDA returned with comments on the Company's allogeneic

KRBP

CORRECTION: IBM Confirms Earlier Reporting Co President Jim Whitehurst Is Stepping Down; Announces Other Leadership Changes

By Benzinga Newsdesk

Today, 5:56 AM

https://newsroom.ibm.com/IBM-Leadership-Changes

IBM

Analyst Ratings

What 20 Analyst Ratings Have To Say About Block

By Benzinga Insights

Today, 5:56 AM

Block (NYSE:SQ) has observed the following analyst ratings within the last quarter:

EF Hutton Maintains Buy on AFC Gamma, Lowers Price Target to $21

Related Posts

Dogecoin Leaps On Elon Musk’s Reported Twitter Payments Plan: Why DOGE Supporters Are Excited

Kiromic BioPharma Provides Update on IND Filings on its Off-the-Shelf, Allogeneic CAR-T for Solid Tumors

CORRECTION: IBM Confirms Earlier Reporting Co President Jim Whitehurst Is Stepping Down; Announces Other Leadership Changes

What 20 Analyst Ratings Have To Say About Block